GLP 1 Medications: Promise, Proof, and Limits for weight loss
A close friend recently asked for my perspective on starting a GLP 1 medication for weight loss.
Her question made me pause and reflect. It signals a broader shift in how we approach weight loss as a medical intervention, and it is being asked with increasing frequency, both in clinics and in everyday conversation.
GLP 1 Medications - An Old Mechanism, A New Magnitude
GLP 1, a naturally occurring incretin hormone involved in appetite regulation, gastric emptying, and insulin secretion, has been understood for years, particularly in diabetes care. The pathway was established. The physiology was known.
What changed was magnitude.
With newer formulations and more potent receptor agonism, randomized controlled trials began demonstrating sustained weight reductions of fifteen to twenty percent. Outcomes once primarily associated with bariatric surgery were now being achieved pharmacologically.
That degree of weight loss carries implications beyond appearance. Sustained reductions at this scale are associated with improvements in blood pressure, glycemic control, fatty liver disease, sleep apnea, and long term cardiovascular risk. The conversation shifted from incremental benefit to metabolic impact.
Yet magnitude alone is not sufficient.
Questions follow naturally:
Who qualifies?
How safe are these drugs long term?
Is weight regained after stopping?
What happens to muscle mass?
Are these medications appropriate for someone without diabetes?
To answer those questions responsibly, we need to move beyond brand names and social media narratives.
Before Ozempic, Wegovy, or Mounjaro, there was physiology. And that is where the conversation has to begin.
The Biology: What Is GLP 1?
Glucagon like peptide 1 (GLP 1) is an incretin hormone released from intestinal L cells in response to nutrient intake. It:
Stimulates insulin secretion in a glucose dependent manner
Suppresses glucagon
Slows gastric emptying
Acts on appetite centers in the brain to increase satiety
Native GLP 1 has a very short half life, approximately 1 to 2 minutes, because it is rapidly degraded by the enzyme dipeptidyl peptidase 4 (DPP 4). Therapeutic use became possible only after the development of longer acting GLP 1 receptor agonists resistant to enzymatic breakdown.
First Generation: Exenatide
Approved by the FDA in 2005 for type 2 diabetes, exenatide was derived from exendin 4, a peptide originally identified in the saliva of the Gila monster.
Randomized controlled trials demonstrated:
HbA1c reductions of roughly 0.5 to 1 percent
Modest weight loss averaging approximately 2 to 3 kilograms
It required twice daily injections and was used primarily for glycemic control in diabetes. It established proof of concept that GLP 1 receptor activation improves both glucose regulation and body weight.
Long Acting GLP 1 Receptor Agonists
Liraglutide
Liraglutide was approved in 2010 for type 2 diabetes and in 2014 for chronic weight management.
In the SCALE Obesity and Prediabetes trial, which enrolled more than 3,700 adults, liraglutide 3.0 mg daily produced approximately 5 to 8 percent mean weight loss over 56 weeks compared with placebo.
The LEADER trial enrolled over 9,000 patients with type 2 diabetes at high cardiovascular risk and demonstrated a statistically significant reduction in major adverse cardiovascular events.
This marked a critical shift. Liraglutide became not only a glucose lowering therapy but a drug with proven cardiovascular benefit in high risk populations.
Semaglutide
Semaglutide was approved in 2017 for type 2 diabetes and in 2021 for chronic weight management at the 2.4 mg weekly dose.
In the STEP 1 trial, adults with overweight or obesity without diabetes experienced approximately 14.9 percent mean weight loss at 68 weeks compared with 2.4 percent with placebo.
The SELECT trial, published in 2023, enrolled more than 17,000 adults with overweight or obesity and established cardiovascular disease but without diabetes. Semaglutide significantly reduced major adverse cardiovascular events compared with placebo.
This is high grade evidence:
Large randomized controlled trials
Hard cardiovascular endpoints
Long follow up
Among currently available agents, semaglutide has one of the most robust evidence bases in both diabetes and obesity populations.
Dual Agonism: Tirzepatide
Tirzepatide activates both the GLP 1 and glucose dependent insulinotropic polypeptide (GIP) receptors.
It was approved in 2022 for type 2 diabetes and in 2023 for chronic weight management.
In the SURMOUNT 1 trial, participants without diabetes achieved up to approximately 20 percent mean weight loss at 72 weeks at the highest dose.
In diabetes trials, HbA1c reductions reached up to 2.4 percent.
A dedicated cardiovascular outcomes trial for obesity populations is ongoing. Earlier diabetes studies demonstrated cardiovascular safety but were not powered to prove superiority.
Triple Agonism: Retatrutide
Retatrutide is an investigational agent that activates GLP 1, GIP, and glucagon receptors.
In a phase 2 randomized controlled trial published in 2023, participants receiving the highest dose achieved approximately 24 percent mean weight loss at 48 weeks. Reductions in liver fat and improvements in several cardiometabolic markers were also observed.
However:
Retatrutide is not yet approved.
Phase 3 trials are ongoing.
Long term safety data are not yet available.
Cardiovascular outcomes trials have not been completed.
Phase 2 results are promising but do not carry the same evidentiary weight as completed large scale outcomes trials.
Safety Profile Across the Class
Common adverse effects include:
Nausea, Vomiting, Diarrhea, Constipation
These effects are dose dependent and most common during dose escalation.
Other considerations include:
Increased risk of gallbladder disease
Rare reports of pancreatitis
Rodent findings of thyroid C cell tumors, leading to boxed warnings
For earlier GLP 1 receptor agonists, human safety data extend beyond a decade. That depth of longitudinal data does not yet exist for newer triple agonists.
Importantly, weight loss with GLP 1 based therapies includes both fat mass and lean mass. In clinical trials, approximately one quarter to one third of total weight loss has been attributed to lean mass. Resistance training and adequate protein intake are important for preserving muscle.
Durability and Discontinuation
Evidence from extension studies shows that discontinuation of semaglutide is associated with substantial weight regain over time.
For many individuals, GLP 1 based therapies function as chronic treatments rather than short term interventions.
This has implications for cost, adherence, monitoring, and long term planning.
The Aesthetic Clinic Expansion
An emerging development is that these medications are increasingly being prescribed in aesthetic and wellness clinics, not only in endocrinology or obesity medicine settings.
This shift reflects demand. It also changes the context of care.
GLP 1 receptor agonists are approved for:
Type 2 diabetes
Obesity defined by BMI criteria
Overweight with weight related comorbidities
They are not approved for cosmetic weight loss in individuals with normal BMI.
When powerful metabolic drugs are framed primarily as aesthetic tools, several implications arise:
1. Indication and Risk Benefit Balance
The tolerance for side effects differs when the primary goal is cosmetic refinement rather than reduction of cardiovascular or metabolic risk.
2. Baseline Assessment and Monitoring
Appropriate use typically includes metabolic assessment, medication review, and structured follow up. The depth of evaluation may vary depending on practice setting.
3. Muscle Preservation
Lean mass loss is a known component of weight reduction. Without resistance training and nutritional counseling, long term metabolic health may be compromised.
4. Chronic Therapy Reality
These medications are often required long term to maintain effect. Short cycles without follow up planning may lead to weight regain.
The expansion into aesthetic clinics is not inherently inappropriate. Many are staffed by qualified physicians. But these are systemic metabolic therapies, not superficial cosmetic interventions. The infrastructure of care matters.
Final Take
GLP 1 based therapies represent one of the most significant advances in metabolic medicine in the past twenty years.
The strength of evidence varies:
Liraglutide and semaglutide: large phase 3 trials and completed cardiovascular outcomes trials
Tirzepatide: strong phase 3 weight loss evidence with ongoing cardiovascular outcomes
Retatrutide: promising phase 2 data with phase 3 and outcomes trials pending
The question is not whether these drugs work. They do.
The more important questions are:
Who derives sufficient cardiometabolic benefit to justify chronic therapy?
What is the long-term safety profile?
How do we preserve muscle and metabolic health alongside weight reduction?
How should these agents be integrated into comprehensive care?
When my friend asked about GLP 1 medications for weight loss, the answer was neither automatic enthusiasm nor reflexive caution.
It was calibration.
Magnitude of weight loss matters. So does what is being lost, including lean mass, and how sustainable the approach is over time.
Evidence maturity and long term safety all deserve consideration.
Responsible use depends on matching the right intervention to the right person, with a clear understanding of both benefits and tradeoffs.
Subscribe to More and Better Years for grounded, evidence based health insights.